Cargando…
Peptide Receptor Radionuclide Therapy in Thyroid Cancer
The treatment options that are currently available for management of metastatic, progressive radioactive iodine (RAI)-refractory differentiated thyroid cancers (DTCs), and medullary thyroid cancers (MTCs) are limited. While there are several systemic targeted therapies, such as tyrosine kinase inhib...
Autores principales: | Gubbi, Sriram, Koch, Christian A., Klubo-Gwiezdzinska, Joanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197113/ https://www.ncbi.nlm.nih.gov/pubmed/35712243 http://dx.doi.org/10.3389/fendo.2022.896287 |
Ejemplares similares
-
Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review
por: Al-Jundi, Mohammad, et al.
Publicado: (2020) -
SAT-502 Clinical Hypothyroidism Associated with Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma: A Novel Adverse Effect of Peptide Receptor Radionuclide Therapy
por: Gubbi, Sriram, et al.
Publicado: (2020) -
Immune Checkpoint Inhibitor Therapy in Neuroendocrine
Tumors
por: Gubbi, Sriram, et al.
Publicado: (2022) -
Co-Occurrence of Familial Non-Medullary Thyroid Cancer (FNMTC) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Associated Tumors—A Cohort Study
por: Aswath, Kshama, et al.
Publicado: (2021) -
Hypertension and COVID-19: Updates from the era of vaccines and variants
por: Swamy, Sowmya, et al.
Publicado: (2021)